Alligator Bioscience to receive million-dollar payments - AbClon partner exercises option
Lund, Sweden, November 7, 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that it will receive payments of more than USD 3.5 million under its collaboration agreement with the South Korean company AbClon Inc. (“AbClon”). This is following the exercising of an option by a third party, Shanghai Henlius Biotech, Inc. (“Henlius”), to expand from a regional to a global agreement. In October 2016, Henlius signed a license agreement with AbClon, encompassing the intellectual property and commercial rights of the monoclonal HER2 antibody AC101 in China (including Taiwan,